Global /China /Healthcare /Drug Manufacturers - General /688076

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.

688076

• SSE: 688076 • Delayed

29.73CNY 1.8%

4.38 USD

As of 26 June 2026, Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. has a market cap of $1.36B USD, ranking #8959 globally and #2385 in China. It ranks #767 in the Healthcare sector, and #289 in the Drug Manufacturers - General industry.

Global Rank

8959

Country Rank

2385

Sector Rank

767

Industry Rank

289

Key Stats

Market Cap

$1.36BUSD

9.24B CNY

Enterprise Value

$1.58BUSD

10.76B CNY

Revenue (TTM)

$286.08MUSD

1.94B CNY

EBITDA (TTM)

$125.83MUSD

854.55M CNY

Net Income (TTM)

$48.95MUSD

332.42M CNY

EBITDA Margin

44%

Profit Margin

17%

PE Ratio

27.6

Forward PE

13.9

PS Ratio

4.8

PB Ratio

3.1

EV/EBITDA

12.6

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Ziquan Tong open_in_new

Employees

2,247

Founded

2009

Website

sinopep.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
1.8%	-1.5%	0.1%	-22%	-24%	-22%	-23%	33%	-49%

News

Markets

Exchange	Ticker	Price	Quotes
Shanghai Stock Exchange (SSE / SHA) MIC: XSHG PRIMARY	688076 江苏诺泰澳赛诺生物制药股份有限公司 Class A ISIN: CNE1000051X5 Shares Out.: Shares Outstanding: 316.052M¹ Shares Float: 183.668M² TV: TradingView: SSE: 688076 SA: Stock Analysis: SHA: 688076 YF: Yahoo Finance: 688076.SS GF: Google Finance: SHA: 688076 BA: Barron's: 688076 MS: Morningstar: XSHG: 688076	29.73 CNY	TV: TradingView: SSE: 688076 SA: Stock Analysis: SHA: 688076 YF: Yahoo Finance: 688076.SS GF: Google Finance: SHA: 688076 BA: Barron's: 688076 MS: Morningstar: XSHG: 688076

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, and sale of peptides, oligonucleotides, and small molecule drugs in China. The company offers Peptide CDMO Services,GMP oligo, full-time equivalent, discovery, generic APIs, and formulation services. It is also involved in professional technical services. The company was founded in 2009 and is headquartered in Hangzhou, China.

Similar Companies

Industry: Drug Manufacturers - General (China)

Name	Market Cap (USD) diff.	PE	Country
Jiangsu Hengrui Pharmaceuticals Co.,Ltd SSE: 600276	$53.73B 364.89B CNY 4K%	44.9	China
WuXi AppTec Co., Ltd. SSE: 603259	$49.53B 336.36B CNY 4K%	17.2	China
Hansoh Pharmaceutical Group Company Ltd. SHEK: 3692	$28.5B 223.48B HKD 2K%	35.7	China
Innovent Biologics, Inc. SHEK: 1801	$18.79B 147.32B HKD 1K%	162.3	China
Sichuan Biokin Pharmaceutical Co.,Ltd. SSE: 688506	$16.48B 111.89B CNY 1K%	-	China
Akeso, Inc. SHEK: 9926	$16.0B 125.46B HKD 1K%	-	China

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 56K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 40K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 26K%	97.4	United States
Roche Holding AG SIX: RO	$316.45B 256.25B CHF 23K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$284.53B 215.59B GBP 21K%	27.6	United Kingdom
Merck & Co., Inc. NYSE: MRK	$274.03B 20K%	15.1	United States

chevron_leftBack